CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Rituximab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01592292
NCT01592292N/ACompleted
CompareCT.gov

A Non-interventional Study for Relative Efficacy Outcome of Rituximab Treatment in RA Patients Who Have Inadequate Response or Have Been Intolerant to a First Anti-TNF Agent

Hoffmann-La Roche·observational·Posted May 7, 2012·Updated Aug 22, 2016

In Brief

An observational study evaluating Rituximab, Adalimumab, and 2 other interventions for Rheumatoid Arthritis. Completed, enrolled 90 participants across 15 sites.

Detailed Summary

This prospective, multi-center, observational study will evaluate the efficacy and the safety of MabThera (rituximab) in participants with rheumatoid arthritis who have not responded or have been intolerant to a first anti-TNF alpha therapy. Participants have commenced MabThera or an alternative anti-TNF alpha treatment as a second biological therapy. Data will be collected for 12 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 7, 2012
Enrollment StartNov 1, 2011
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.2 years ago

Interventions

Rituximabdrug

Rituximab as per physician's discretion.

Adalimumabdrug

Adalimumab as per physician's discretion.

Etanerceptdrug

Etanercept as per physician's discretion.

Infliximabdrug

Infliximab as per physician's discretion.